Multidrug resistance in cancer: role of ATP–dependent transporters
The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common mechanism of multidrug resistance consists in the overexpression of cancer drug–extruding ABC transporters in malignant cells (58).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [58]
In the citing paper
“Prior exposure to taxanes during treatment of mCRPC can induce resistance mechanisms, including upregulation of efflux pumps or mutations in tubulin, that may compromise the efficacy of microtubule inhibitor-based ADCs246,247.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [247]
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“But why can some patients be cured by these approaches and others respond transiently or incompletely? Host and tumour genetic alterations, epigenetic changes and tumour environment all seem to contribute to the complex story of cancer drug resistanc”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322 · cited 1×
“cgi?l=9429">ABCG2 — also known as MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC transporter in placenta”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“Recent studies have emphasized the importance of the tumour vasculature and an appropriate pressure gradient for adequate drug delivery to the tumou”
BackgroundBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“asp?DrugCode=A%2D10166&DrugName=PACLITAXEL%2CSEMI%2DSYNTHETIC+INTRAVEN%2E&DrugType=1">paclitaxel”
Self-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The discovery of MRP1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detai”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Research works printed but not linked: 3
- Solary, E. et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68, 1714–1719 (1991). · doi:10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2
- Abraham, J. et al. A phase I study of the novel P-glycoprotein (PGP) antagonist, XR9576 in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol. 20, 287 (2001).
- Fedeli, L. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805–1811 (1989). · doi:10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d
Cited by
Items 101–200 of 1,041
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
“ABCG2 Curcumin Colon (297) AC C EP TE D M AN U SC R IP T ABCG2 Imatinib, nilotinib Hematopoietic (298) ABCG2 Mithramycin Lung, esophageal (299)”
InfluentialHow Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Gerlinger, M., & Swanton, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605912 · Cited by 421
“The rapid acquisition of tumours to non-cross resistant cytotoxics, which the tumour has not yet been exposed to, is a major cause of treatment failure in patients who relapse after chemotherapy (Gottesman et al, 2002).”
Structure of the human multidrug transporter ABCG2
Taylor, N. M. I., Manolaridis, I., Jackson, S. M., Kowal, J., Stahlberg, H., & Locher, K. P. (2017) · Nature · doi:10.1038/nature22345 · Cited by 418
El-Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El-Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 431
The use of a glucose-reduced graphene oxide suspension for photothermal cancer therapy
Akhavan, O., Ghaderi, E., Aghayee, S., Fereydooni, Y., & Talebi, A. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm31396k · Cited by 433
“cancer cells [3,4]) which should be resolved.”
Structure and mechanism of ATP-binding cassette transporters
Locher, K. P. (2009) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0125 · Cited by 414
“However, many are involved in multi-drug extrusion of toxic substances, which can lead to resistance of cancer cells against drugs used in chemotherapy (Gottesman et al. 2002).”
BackgroundReceptor-targeted nanocarriers for therapeutic delivery to cancer
Yu, B., Tai, H. C., Xue, W., Lee, L. J., & Lee, R. J. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.521200 · Cited by 423
“In addition, delivery via nanocarriers has been reported to overcome multidrug resistance (MDR) caused by drug efflux transporters such as the P-glycoprotein, which are frequently overexpressed in cancer cells (Gottesman et al. 2002, Piddock 2006).”
Asanuma, D., Sakabe, M., Kamiya, M., Yamamoto, K., Hiratake, J., Ogawa, M., Kosaka, N., Choyke, P. L., Nagano, T., Kobayashi, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7463 · Cited by 418
“1 for details, including the chemical structures), which are often overexpressed in metastatic cancers and cause multidrug resistance 26 .”
ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance
Begicevic, R.-R., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112362 · Cited by 395
“The MDR subfamily of transporters are mainly localized in human tissue of the brain, lung, breast, kidneys, liver, ovaries, prostate, placenta and the pancreas [46] (Table 1) and play a critical role in the protection of normal cells.”
BackgroundMolecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 407
“Resistance results because increased drug efflux lowers intracellular drug concentration hence, decreasing their intracellular effects [25].”
BackgroundDomingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., Rodriguez-Barrueco, R., Bonal, D. M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.016 · Cited by 416
“Taken together, these data suggest that Notch and Hedgehog signaling regulate the activation of AKT and expression of Bcl-2, respectively, to promote survival and multidrug resistance in a P-gp/ABCB1 drug efflux independent mechanism.”
BackgroundInfluentialFekete, J. T., & Győrffy, B. (2019) · International Journal of Cancer · doi:10.1002/ijc.32369 · Cited by 422
Co–Ferrocene MOF/Glucose Oxidase as Cascade Nanozyme for Effective Tumor Therapy
Fang, C., Deng, Z., Cao, G., Chu, Q., Wu, Y., Li, X., Peng, X., & Han, G. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910085 · Cited by 423
Saxena, M., Stephens, M. A., Pathak, H., & Rangarajan, A. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.61 · Cited by 408
“Those that respond to chemotherapy at the start of the treatment can often simultaneously become resistant to different classes of drugs resulting in multidrug resistance (MDR).(2) Development of MDR is also the leading cause of cancer recurrence, with the resultant cancers behaving more aggressive than at the start o…”
BackgroundInfluentialPharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 371
“Interestingly, overexpression of the ABCB1 gene in cancer cells induced resistance to chemotherapeutic agents [110].”
BackgroundCytometric assessment of mitochondria using fluorescent probes
Cottet‐Rousselle, C., Ronot, X., Leverve, X., & Mayol, J. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21061 · Cited by 399
“However, the main mechanism is the overexpression of drug-transmembrane transporter proteins (116).”
BackgroundMolecular mechanisms for tumour resistance to chemotherapy
Pan, S., Li, Z., He, Z., Qiu, J., & Zhou, S. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12581 · Cited by 401
Recent Advances in the Application of Vitamin E TPGS for Drug Delivery
Yang, C., Wu, T., Qi, Y., & Zhang, Z. (2018) · Theranostics · doi:10.7150/thno.22711 · Cited by 402
“What’s worse, decades of research has identified that this phenomenon exists in nearly every effective drug, even the newest therapeutic agents [9].”
BackgroundAdvances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 384
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment: Miniperspective
Waghray, D., & Zhang, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01457 · Cited by 400
Mechanisms and strategies to overcome multiple drug resistance in cancer
Ozben, T. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.02.020 · Cited by 406
“results from elevated expression of particular proteins, such as cell-membrane transporters, which can result in an increased efflux of the cytotoxic drugs from the cancer cells, thus lowering their intracellular concentrations [4,6,9].”
BackgroundInfluentialAn overview of cancer multidrug resistance: a still unsolved problem
Lage, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8111-5 · Cited by 408
“3 Lage, H. (2003) ABC-transporters: implications on drug resistance from microorganisms to human cancers.”
BackgroundInfluentialA role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms
Cojoc, M., Mäbert, K., Muders, M. H., & Dubrovska, A. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.06.004 · Cited by 393
Multi-functional nanocarriers to overcome tumor drug resistance
Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.04.003 · Cited by 407
“In addition to its role in MDR cancer, it is a critical component of the blood brain barrier (BBB), providing neuroprotection [5].”
BackgroundInfluentialABCG2: determining its relevance in clinical drug resistance
Robey, R. W., Polgar, O., Deeken, J., To, K. W., & Bates, S. E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9042-6 · Cited by 387
“Pgp is known to transport a wide range of chemotherapeutic agents including the anthracyclines, vincas, taxanes, etoposide, and mitoxantrone [1].”
BackgroundSelf-citationAnticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Gao, Y., Chen, Y., Ji, X., He, X., Yin, Q., Zhang, Z., Shi, J., & Li, Y. (2011) · ACS Nano · doi:10.1021/nn2033105 · Cited by 400
“T he development of multidrug resistance (MDR) is one of the main obstacles to effective cancer treatment.(1)”
BackgroundNies, A. T., Jedlitschky, G., König, J., Herold-Mende, C., Steiner, H. H., Schmitt, H.-P., & Keppler, D. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.07.051 · Cited by 379
Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery
Kesharwani, P., & Iyer, A. K. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.012 · Cited by 380
“More importantly, cancer chemotherapy can fail or lead to further complications as a result of suboptimal drug dose reaching the target cancer cells, eventually leading to formation of MDR cancers [57].”
BackgroundWang, S., Li, F., Qiao, R., Hu, X., Liao, H., Chen, L., Wu, J., Wu, H., Zhao, M., Liu, J., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b06399 · Cited by 381
Cohen-Zinder, M., Seroussi, E., Larkin, D. M., Loor, J. J., Wind, A. E.-V. D., Lee, J.-H., Drackley, J. K., Band, M. R., Hernandez, A. G., Shani, M., et al. (2005) · Genome Research · doi:10.1101/gr.3806705 · Cited by 377
“ABCG2, a member of the ATP binding cassette (ABC) superfamily, is a “halftransporter,” with only one ATP binding cassette in the N terminus and one C-terminal transmembrane domain (Ejendal and Hrycyna 2002; Gottesman et al. 2002).”
BackgroundStimuli‐Responsive Materials for Controlled Release of Theranostic Agents
Wang, Y., Shim, M. S., Levinson, N. S., Sung, H., & Xia, Y. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201400279 · Cited by 378
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials
Chen, W., Luo, G., & Zhang, X. (2019) · Advanced Materials · doi:10.1002/adma.201802725 · Cited by 373
Herbal Modulation of P‐Glycoprotein
Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375
“Overexpression of Pgp has been associated with the clinical multidrug resistance (MDR) phenotype and poor prognosis for many human cancers (Ambudkar et al., 1999; Borst and Elferink, 2002; Gottesman, 2002; Gottesman et al., 2002).”
BackgroundWei, T., Chen, C., Liu, J., Liu, C., Posocco, P., Liu, X., Cheng, Q., Huo, S., Liang, Z., Fermeglia, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418494112 · Cited by 370
“Angew Chem Int Ed Engl 51(34):8478–8484.”
BackgroundThermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes
Chakravarty, P., Marches, R., Zimmerman, N. S., Swafford, A. D.-E., Bajaj, P., Musselman, I. H., Pantano, P., Draper, R. K., & Vitetta, E. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803557105 · Cited by 374
“In addition, tumor cells develop resistance to many chemotherapeutic agents (1), and most chemotherapeutic drugs kill dividing cancer cells and not dormant ones.”
BackgroundA new era of cancer treatment: carbon nanotubes as drug delivery tools
Seifalian, A. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s16923 · Cited by 366
Schmidt, S., Rainer, J., Ploner, C., Presul, E., Riml, S., & Kofler, R. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401456 · Cited by 360
“expression has been made responsible for GC resistance in a mouse thymoma line,(90) but what role this form of GC resistance might play in patients is not clear.(8,88,91) Finally,”
BackgroundMechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
Coley, H. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.007 · Cited by 351
Multi-functional polymeric nanoparticles for tumour-targeted drug delivery
van Vlerken, L. E., & Amiji, M. M. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.2.205 · Cited by 352
Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition
Robey, R. W., Steadman, K., Polgar, O., Morisaki, K., Blayney, M., Mistry, P., & Bates, S. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3298 · Cited by 350
“Overexpression of ATP-binding cassette (ABC) transporters in cancer cells is associated with the multidrug resistance phenotype (1).”
BackgroundSelf-citationVinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead
Martino, E., Casamassima, G., Castiglione, S., Cellupica, E., Pantalone, S., Papagni, F., Rui, M., Siciliano, A. M., & Collina, S. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.06.044 · Cited by 337
Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis
Yang, Y., Zhang, Z., Li, S., Ye, X., Li, X., & He, K. (2014) · Fitoterapia · doi:10.1016/j.fitote.2013.10.010 · Cited by 333
Cell-Specific Delivery of Diverse Cargos by Bacteriophage MS2 Virus-like Particles
Ashley, C. E., Carnes, E. C., Phillips, G. K., Durfee, P. N., Buley, M. D., Lino, C. A., Padilla, D. P., Phillips, B., Carter, M. B., Willman, C. L., et al. (2011) · ACS Nano · doi:10.1021/nn201397z · Cited by 350
“Targeted nanocarriers internalized via receptor-mediated endocytosis are typically able to circumvent Pgp efflux mechanisms and can, therefore, kill MDR cancer cells at lower drug concentrations.(23,24)”
Cystine-Glutamate Transporter SLC7A11 in Cancer Chemosensitivity and Chemoresistance
Huang, Y., Dai, Z., Barbacioru, C., & Sadée, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4267 · Cited by 340
Duan, C., Yu, M., Xu, J., Li, B.-Y., Zhao, Y., & Kankala, R. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114643 · Cited by 335
Li, Y., Zou, L., Li, Q., Haibe-Kains, B., Tian, R., Li, Y., Desmedt, C., Sotiriou, C., Szallasi, Z., Iglehart, J. D., et al. (2010) · Nature Medicine · doi:10.1038/nm.2090 · Cited by 352
Abou-Donia, M. B., El-Masry, E. M., Abdel-Rahman, A. A., McLendon, R. E., & Schiffman, S. S. (2008) · Journal of Toxicology and Environmental Health, Part A · doi:10.1080/15287390802328630 · Cited by 333
“…resistance that is associated with the chronic use of anticancer agents such as anthracyclines (doxorubicin and daunorubicin) and vinca alkaloids (vinblastine and vincristine); i.e., increased P-gp efflux lowers intracellular drug concentrations in neoplastic tissues (Gottesman et al., 2002).”
BackgroundHigh-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter
Özvegy-Laczka, C., Hegedűs, T., Várady, G., Ujhelly, O., Schuetz, J. D., Váradi, A., Kéri, G., Őrfi, L., Német, K., & Sarkadi, B. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1485 · Cited by 340
“1485 at A SPE T Journals on July 6, 2017 m olpharm .aspetjournals.org D ow nloaded from 2002; Gottesman et al., 2002).”
BackgroundXi, Y., Ge, J., Wang, M., Chen, M., Niu, W., Cheng, W., Xue, Y., Lin, C., & Lei, B. (2020) · ACS Nano · doi:10.1021/acsnano.9b07173 · Cited by 346
Nanoparticles as carriers for drug delivery in cancer
Dadwal, A., Baldi, A., & Kumar Narang, R. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2018.1457039 · Cited by 335
“MDR occurs because of the overexpression of transporter proteins that expel drugs from cells on the surface of cancer cells [4,19,20].”
BackgroundDrug resistance in metastatic castration-resistant prostate cancer
Seruga, B., Ocana, A., & Tannock, I. F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 336
Petersen, N. H. T., Olsen, O. D., Groth-Pedersen, L., Ellegaard, A.-M., Bilgin, M., Redmer, S., Ostenfeld, M. S., Ulanet, D., Dovmark, T. H., Lønborg, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.003 · Cited by 337
“Ca increasing the expression of multidrug resistance (MDR) proteins, P-glycoproteins of the ATP-binding cassette transporter family (Gottesman et al., 2002).”
Role of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
The role of photodynamic therapy in overcoming cancer drug resistance
Spring, B. Q., Rizvi, I., Xu, N., & Hasan, T. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00495g · Cited by 335
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
Li, L., Tang, F., Liu, H., Liu, T., Hao, N., Chen, D., Teng, X., & He, J. (2010) · ACS Nano · doi:10.1021/nn100918a · Cited by 332
“Thus it can increase the cell internalization, decrease the drug efflux, and increase the intracellular accumulation of the drugs.(31,32) The cytotoxicity of the SN-PEG-Dtxl was evaluated and compared with free Dtxl via the MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.”
MethodStructural basis of small-molecule inhibition of human multidrug transporter ABCG2
Jackson, S. M., Manolaridis, I., Kowal, J., Zechner, M., Taylor, N. M. I., Bause, M., Bauer, S., Bartholomaeus, R., Bernhardt, G., Koenig, B., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0049-1 · Cited by 321
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J.-P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 327
“Once it was shown that P-gp could not transport cisplatin (72, 73), alternative transporters were sought along two possible lines: either the overexpression of a transporter that effluxes cisplatin (see also the discussion on glutathione below) or the downregulation of an influx transporter.”
BackgroundInfluentialSelf-citationTargeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Liang, Z., Wu, H., Xia, J., Li, Y., Zhang, Y., Huang, K., Wagar, N., Yoon, Y., Cho, H. T., Scala, S., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.10.017 · Cited by 330
“MDR is the ability of tumor cells to resist several unrelated drugs after exposure to a single chemotherapy drug [2] and is the leading cause of cancer-related death.”
BackgroundTransferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy
Tortorella, S., & Karagiannis, T. C. (2014) · The Journal of Membrane Biology · doi:10.1007/s00232-014-9637-0 · Cited by 312
“There are two mechanisms of resistance: (1) the impaired delivery of anticancer drug to tumour cells, and (2) the genetic and epigenetic alterations in malignant cells that affect their drug sensitivity (Gottesman et al. 2002).”
BackgroundMultidrug resistance associated proteins in multidrug resistance
Sodani, K., Patel, A., Kathawala, R. J., & Chen, Z.-S. (2012) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10329 · Cited by 300
Melatonin: an inhibitor of breast cancer
Hill, S. M., Belancio, V. P., Dauchy, R. T., Xiang, S., Brimer, S., Mao, L., Hauch, A., Lundberg, P. W., Summers, W., Yuan, L., et al. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0030 · Cited by 317
“Furthermore, intrinsic or acquired resistance to endocrine therapies or chemotherapeutic drugs has also been linked to the up-regulation of ABC transporter efflux molecules (Gottesman et al. 2002), such as ABCB1 (MDR-1/P-gp), ABCC1 (MRP1), and ABCG2 (or breast cancer resistance protein, BCRP), as well as to the up-reg…”
BackgroundKim, D., Xing, T., Yang, Z., Dudek, R., Lu, Q., & Chen, Y.-H. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm7010001 · Cited by 306
“, paclitaxel, doxorubicin, or vincristine) frequently results in multidrug resistance due to increased ABC transporter expression [114].”
BackgroundSambi, M., Bagheri, L., & Szewczuk, M. R. (2019) · Journal of Oncology · doi:10.1155/2019/4508794 · Cited by 313
Mizuarai, S., Aozasa, N., & Kotani, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.11669 · Cited by 318
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Interaction of tumor-associated macrophages and cancer chemotherapy
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322
“ABC transporters, aberrant transcription factor nuclear factor-κB (NF-κB) activity, and the mechanisms of damaged DNA repair.(7,86,87) CT can also lead to the selective expansion of resistant cancer clones.”
BackgroundExploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
Enriquez-Navas, P. M., Kam, Y., Das, T., Hassan, S., Silva, A., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7842 · Cited by 322
The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer
Thapa, R., & Wilson, G. D. (2016) · Stem Cells International · doi:10.1155/2016/2087204 · Cited by 312
Glutathione in Cancer Cell Death
Ortega, A. L., Mena, S., & Estrela, J. M. (2011) · Cancers · doi:10.3390/cancers3011285 · Cited by 317
“But MRP-1, MRP-2 and MRP-4 are principally responsible for the transport of GSH [127,129,130], whereas the others MRPs have different substrates (e.g., bilirubin glucuronosides for MRP2 and MRP3, or cyclic AMP and cyclic GMP for MRP4, MRP5, and MRP8) [130].”
BackgroundInfluentialPatil, Y., Sadhukha, T., Ma, L., & Panyam, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.021 · Cited by 317
Resistance to chemotherapy: new treatments and novel insights into an old problem
Raguz, S., & Yagüe, E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604510 · Cited by 312
“Although these compounds proved to be ineffective or toxic at the doses required to attenuate P-glycoprotein function, some clinical trials indicated that modulation of P-glycoprotein function could be achieved (Gottesman et al, 2002).”
InfluentialMaher, J. M., Dieter, M. Z., Aleksunes, L. M., Slitt, A. L., Guo, G., Tanaka, Y., Scheffer, G. L., Chan, J. Y., Manautou, J. E., Chen, Y., et al. (2007) · Hepatology · doi:10.1002/hep.21831 · Cited by 315
Molecular biomarkers in acute myeloid leukemia
Prada-Arismendy, J., Arroyave, J. C., & Röthlisberger, S. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 304
Electrospun Fibrous Architectures for Drug Delivery, Tissue Engineering and Cancer Therapy
Ding, Y., Li, W., Zhang, F., Liu, Z., Zanjanizadeh Ezazi, N., Liu, D., & Santos, H. A. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201802852 · Cited by 312
Hu, Q., Sun, W., Wang, J., Ruan, H., Zhang, X., Ye, Y., Shen, S., Wang, C., Lu, W., Cheng, K., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0310-2 · Cited by 310
Goldstein, D. B., Tate, S. K., & Sisodiya, S. M. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1229 · Cited by 312
“It is only recently that the role of drug transporters in multidrug resistance in anti-tumour therapy has sparked interest in transporter pharmacogenetic”
BackgroundCollateral sensitivity as a strategy against cancer multidrug resistance
Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.002 · Cited by 305
“Mulidrug resistance (MDR) is characterized by the simultaneous esistance to drugs that differ both structurally and mechaistically (Gottesman et al., 2002).”
BackgroundSelf-citationIllmer, T., Schaich, M., Platzbecker, U., Freiberg-Richter, J., Oelschlägel, U., von Bonin, M., Pursche, S., Bergemann, T., Ehninger, G., & Schleyer, E. (2004) · Leukemia · doi:10.1038/sj.leu.2403257 · Cited by 307
Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., Fleming, D. R., et al. (2005) · Cancer · doi:10.1002/cncr.21227 · Cited by 302
“P-gp is an adenosine triphosphate (ATP)-dependent drug efflux pump that expels several structurally and functionally unrelated antitumor drugs, including anthracyclines, vinca alkaloids, epipodophyllotoxins, and taxanes, from cells.(1) In a meta-analysis of P-gp expression in breast carcinoma, the investigators conclu…”
BackgroundBronger, H., König, J., Kopplow, K., Steiner, H.-H., Ahmadi, R., Herold-Mende, C., Keppler, D., & Nies, A. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1271 · Cited by 295
“The investigation of ATP-dependent efflux pumps conferring MDR has become a major topic in the exploration of tumor chemoresistance (28).”
BackgroundPatil, Y. B., Swaminathan, S. K., Sadhukha, T., Ma, L., & Panyam, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.048 · Cited by 304
“, PSC833, VX-710) had better tolerability but were limited by unpredictable pharmacokinetic interactions with the anticancer drug and interactions with other transport proteins [9,10].”
BackgroundMa, Y., Yang, Y., Wang, F., Moyer, M.-P., Wei, Q., Zhang, P., Yang, Z., Liu, W., Zhang, H., Chen, N., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308392 · Cited by 304
Recent advances (2015–2016) in anticancer hybrids
Kerru, N., Singh, P., Koorbanally, N., Raj, R., & Kumar, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.033 · Cited by 295
Fibroblast activation in cancer: when seed fertilizes soil
Kuzet, S.-E., & Gaggioli, C. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2467-x · Cited by 290
“Such proteins belong to a family of ABC transporters that allow cancer cells to eliminate antitumor drugs (Gottesman et al. 2002).”
ABC-transporters: implications on drug resistance from microorganisms to human cancers
Lage, H. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00203-6 · Cited by 298
“A large number of different multidrug transporter proteins have since been identified in cancer cells [3] as well as in pathogenic microorganisms [4].”
BackgroundPaterson, B. M., & Donnelly, P. S. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00215a · Cited by 299
Riganti, C., Miraglia, E., Viarisio, D., Costamagna, C., Pescarmona, G., Ghigo, D., & Bosia, A. (2005) · Cancer Research · doi:10.1158/0008-5472.516.65.2 · Cited by 271
“their substrates, has led to the development of compounds that try to reverse MDR with different mechanisms (1, 4).”
BackgroundResultInfluentialJiang, L., Li, L., He, X., Yi, Q., He, B., Cao, J., Pan, W., & Gu, Z. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.004 · Cited by 294
Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro
Kievit, F. M., Wang, F. Y., Fang, C., Mok, H., Wang, K., Silber, J. R., Ellenbogen, R. G., & Zhang, M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.024 · Cited by 289
“Treatment of approximately 50% of human cancers includes the use of chemotherapy [1].”
BackgroundWang, T., Wang, D., Yu, H., Wang, M., Liu, J., Feng, B., Zhou, F., Yin, Q., Zhang, Z., Huang, Y., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b07706 · Cited by 295
Nanayakkara, A. K., Follit, C. A., Chen, G., Williams, N. S., Vogel, P. D., & Wise, J. G. (2018) · Scientific Reports · doi:10.1038/s41598-018-19325-x · Cited by 282
Wang, L., Zhang, T., Li, P., Huang, W., Tang, J., Wang, P., Liu, J., Yuan, Q., Bai, R., Li, B., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b02483 · Cited by 290
“In general, metal transport proteins or genes including ATP-binding cassette transporter subfamily C member C1 (ABCC1), divalent metal transporter 1(DMT1) and copper-transporting ATPase 1 (ATP7A) are responsible for transporting or excluding metal ions and metal-bound molecules.(34,38,68,69) We found that THP-1 cells…”
BackgroundTaxol®: The First Microtubule Stabilizing Agent
Yang, C.-P., & Horwitz, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081733 · Cited by 284
Dong, X., Mattingly, C. A., Tseng, M. T., Cho, M. J., Liu, Y., Adams, V. R., & Mumper, R. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2747 · Cited by 290
“P-glycoprotein (P-gp) encoded by the mdr1 gene is well-characterized and known to be a clinically important transporter protein belonging to the ATP-binding cassette family of membrane transporters (2).”
Metadata
- Authors
- Gottesman, M. M., Fojo, T., & Bates, S. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fojo, Tito
- Venue
- Nature Reviews Cancer
- Published
- 2002-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 48-58
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2006434892
- Cited by
- 5,536
- References
- 168
- Citations by year
- 2026: 144 · 2025: 173 · 2024: 183 · 2023: 228 · 2022: 231 · 2021: 257 · 2020: 305 · 2019: 281 · 2018: 318 · 2017: 322 · 2016: 329 · 2015: 333 · 2014: 326 · 2013: 296 · 2012: 274
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Keywords
- multidrug resistance, drug efflux pumps, chemoresistance, cancer chemotherapy, drug resistance mechanisms, metastatic cancer
- MeSH terms
- Adenosine Triphosphate, Antineoplastic Agents, Breast Neoplasms, Female, Forecasting, Multigene Family, Humans, Leukemia, Neoplasm Proteins, Neoplasms, Organ Specificity, Permeability, Structure-Activity Relationship, Drug Design, Xenobiotics, Biomarkers, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.